早期腰大池引流联合鞘内尿激酶治疗重型动脉瘤性蛛网膜下腔出血:LD-ITUK随机对照试验方案
针对重型动脉瘤性蛛网膜下腔出血(SaSAH)患者,本研究为研究者发起的多中心、前瞻性、随机、双盲、安慰剂对照优效性试验,计划纳入424例成人患者,1:1随机比较腰大池引流联合鞘内尿激酶(LD-ITUK)与腰大池引流联合鞘内生理盐水在标准治疗基础上的疗效。主要结局为发病180天时改良Rankin量表(mRS)评分0-2分的良好功能结局比例,由独立结局裁定委员会盲法判定。
要点
- LD-ITUK为在标准治疗基础上联合腰大池引流与鞘内尿激酶,对照为腰大池引流加鞘内生理盐水。
- 纳入标准为首次aSAH、Hunt-Hess III-V级、发病48小时内已处理动脉瘤的成人患者。
- 主要结局为180天mRS 0-2分的良好功能结局比例,由盲法独立委员会裁定。
核心结论
- 该试验旨在确定LD-ITUK相比当前标准治疗能否改善SaSAH患者的长期功能结局。
研究设计与样本
- 研究者发起的多中心、前瞻性、随机、双盲、安慰剂对照优效性试验。
- 计划纳入424例符合条件的SaSAH患者,按1:1比例随机分配至干预组或对照组。
- 干预组接受腰大池引流联合鞘内尿激酶(LD-ITUK),对照组接受腰大池引流联合鞘内生理盐水,均附加于标准治疗。
关键数值与推荐
- 纳入标准:成人、首次aSAH、临床分级Hunt-Hess III至V级、责任动脉瘤在发病48小时内经手术夹闭或血管内栓塞处理。
- 主要结局:发病180天时mRS评分0至2分的患者比例,由对治疗分配不知情的独立结局裁定委员会(OAC)判定。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Despite advances in embolization techniques and neurocritical care, patients with severe aneurysmal subarachnoid hemorrhage (SaSAH) continue to face substantial risk of morbidity and long-term disability. The presence of subarachnoid blood and its breakdown products significantly contributes to secondary brain injury and subsequent complications. Although the EARLYDRAIN trial demonstrated a benefit from lumbar drainage in clearing blood, this method alone is insufficient to remove clots located above the fourth ventricle. Urokinase, a fibrinolytic agent, offers a potential means to enhance clot clearance. However, the combined strategy of lumbar drainage plus intrathecal urokinase (LD-ITUK) has not yet been rigorously evaluated. METHODS/DESIGN: This is an investigator-initiated, multicenter, prospective, randomized, double-blind, placebo-controlled superiority trial. It aims to compare the efficacy of LD-ITUK against lumbar drainage alone (with intrathecal saline) in patients with SaSAH, when added to standard care. A total of 424 eligible patients will be randomized in a 1:1 ratio to receive either the intervention (LD-ITUK) or the control treatment (lumbar drainage plus intrathecal saline). Eligible participants are adults with a first-episode aSAH, clinically graded as Hunt-Hess III to V, whose ruptured aneurysm has been secured via surgical clipping or endovascular coiling within 48 h after onset. The primary outcome is the proportion of patients achieving a favorable functional outcome, defined as a modified Rankin Scale (mRS) score of 0 to 2 at 180 days after onset, as adjudicated by an independent Outcome Adjudication Committee (OAC) blinded to treatment allocation. DISCUSSION: This trial will determine whether the LD-ITUK method could improve the long-term functional outcomes compared to the current standard treatment in patients with SaSAH. TRIAL REGISTRATION: ClinicalTrials.gov NCT06284642. Registered 28 February 2024.
引用
- Wu M, Yan T, Hu P, et al. Early lumbar drainage plus intrathecal urokinase in severe aneurysmal subarachnoid hemorrhage: the LD-ITUK randomized controlled trial protocol. Trials. 2026. PMID: 41968344. doi:10.1186/s13063-026-09716-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。